Skip Ribbon Commands
Skip to main content

The NCCS' Humphrey Oei Distinguished Lecture Series 2019

​An Evidence-based Methodology to Select Patients for Proton Therapy

and Clinical Validation.

Date & Time: Tuesday, 15 October 2019, 12.00pm to 2.00pm 

Lunch: 12.00pm to 1.00pm  |  Lecture: 1.00pm to 2.00pm

Venue: National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610

Peter & Mary Fu Auditorium, Level 4


Programme Synopsis

The relationship between 3-dimensional dose distributions and risks on radiation-induced side effects can be described

by Normal Tissue Complication Probability (NTCP) models. NTCP-models may contain only one dose-volume predictor

(dose metrics), but generally the performance of these model significantly improve when adding multiple other predictors

(multivariable NTCP-models). 


According to the model-based approach, next to outcome prediction, NTCP-models can be

applied for dose optimization, selecting the best radiation technology, plan adaptation and even technology validation. 


For many side-effects, the risk may depend on more than one dose metrics to different organs at risk (OARs). To produce

treatment plans that eventually result in adequate target dose coverage with the lowest probability on side effects, dose

distributions to OARs should be translated into NTCP-profiles using NTCP-models (model-based dose optimization). For

the selection of the best treatment plan, or even for the selection of patients for more advanced radiation technologies,

like protons, information on NTCP-profiles next to dose profiles are essential to ultimately obtain the best clinical result.


Distinguished Speaker

Professor Johannes “Hans” A. Langendijk studied Medicine at the VU University in

Amsterdam. He was trained as a radiotherapist-oncologist at the Radiotherapeutic

Institute Limburg in Heerlen and Maasricht.  


From 1997 to 2004, he worked as a radiotherapist-oncologist at the Radiotherapy

department of the VU Medical Center in Amsterdam. During that period he further

specialised in radiotherapy of tumors in the main neck area. 


In October 2004, he worked as a professor / department head at the Radiotherapy

department of the University Medical Center Groningen. He is particularly interested

in head and neck oncology, prevention of radiation-induced complications and the

development of innovative methods for the development and clinical validation of new

radiotherapy techniques, such as proton therapy.  Hans Langendijk holds various administrative positions at home and abroad,

including as chairman of the Landelijk Platform Protonentherapie (LPPT) [National Proton Therapy Platform] and within the European

Proton Therapy Platform (EPTN).



The NCCS' Humphrey Oei Distinguished Lecture Series aspire to be one of Singapore's leading

forums or intellectual inquiry and discussion in cancer and biological research. With eminent

scientists as a guest speakers, the series hopes to create an environment for exploration of ideas

and advances in cancer biology and medicine.

This lecture series is brought to you by the National Cancer Centre Singapore.

Seats are limited and online registration is required for admission.Doctors attending the lecture will be

awarded with one CME point.



For more information, please email us at communitypartnership@nccs.com.sg  or contact us at 6352 0772 .

Scan the QR Code to register online! Or go to: http://bit.ly/2mm8pCP